Home » Stocks » ISEE

IVERIC bio, Inc. (ISEE)

Stock Price: $5.99 USD 0.19 (3.28%)
Updated November 23, 4:00 PM EST - Market closed
After-hours: $5.96 -0.03 (-0.50%) Nov 23, 5:06 PM

Stock Price Chart

Key Info

Market Cap 536.51M
Revenue (ttm) n/a
Net Income (ttm) -76.59M
Shares Out 89.57M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $5.99
Previous Close $5.80
Change ($) 0.19
Change (%) 3.28%
Day's Open 5.90
Day's Range 5.76 - 6.11
Day's Volume 630,232
52-Week Range 2.64 - 8.97

More Stats

Market Cap 536.51M
Enterprise Value 305.52M
Earnings Date (est) Mar 2, 2021
Ex-Dividend Date n/a
Shares Outstanding 89.57M
Float 76.78M
EPS (basic) -1.26
EPS (diluted) -1.23
FCF / Share -0.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.38M
Short Ratio 3.58
Short % of Float 4.40%
Beta 1.66
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.36
Revenue n/a
Operating Income -81.08M
Net Income -76.59M
Free Cash Flow -56.94M
Net Cash 230.99M
Net Cash / Share 2.58
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -30.40%
ROE -50.38%
ROIC -438.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(117.03% upside)
Current: $5.99
Target: 13.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth--312.46%-1.16%24.83%----
Gross Profit--21050.9151.5141.26---
Operating Income-61.27-65.35108-196-124-80.51-47.43-13.68-19.63
Net Income-58.8663.09114-193-106-117-51.15-14.56-18.63
Shares Outstanding42.2237.0635.9235.4934.5833.269.001.451.39
Earnings Per Share-1.391.703.17-5.45-3.06-3.51-6.34-14.89-18.27
EPS Growth--46.37%-------
Operating Cash Flow-48.49-41.91-122-109-78.53111-48.78-13.10-19.12
Capital Expenditures0.15---0.57-2.61-1.66-0.01--
Free Cash Flow-48.34-41.91-122-109-81.14109-48.78-13.10-19.13
Cash & Equivalents1261311672892974642114.306.40
Total Debt0.50------11.04-
Net Cash / Debt125131167289297464211-6.746.40
Book Value11712438.04-94.6259.95129170-123-102
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name IVERIC bio, Inc.
Country United States
Employees 55
CEO Glenn P. Sblendorio

Stock Information

Ticker Symbol ISEE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ISEE


IVERIC bio, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. It is also developing High temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company has a license agreement with the University of Florida Research Foundation and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and Best disease and other BEST1-related inherited retinal diseases. It also has a research agreement with the University of Massachusetts Medical School to develop gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and autosomal recessive Stargardt disease; and IRDs associated with mutations in the USH2A gene. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.